Sphaera Pharma

What Sphaera Pharma does

Sphaera Pharma Pvt Ltd is a privately held drug discovery and development biotech founded in 2007 and headquartered in Gurugram, Haryana, India. The company operates an integrated preclinical R&D platform spanning medicinal chemistry (NCE design and synthesis, hit-to-lead and lead optimization, and compound library design across heterocycles, steroids, and PROTAC scaffolds), in-vitro pharmacology (enzymatic and cell-based assays, biomarker profiling, ADME studies), and in-vivo pharmacology (preclinical efficacy, safety, and pharmacokinetic models in rodents, including disease-specific models). Therapeutic area expertise covers oncology, metabolic disorders, CNS, mitochondrial dysfunction, and rare genetic disorders, with a particular focus on drug repurposing for rare and neglected diseases via proprietary platform technologies.

The company's business model combines fee-for-service preclinical R&D engagements with global pharmaceutical and biotech partners and collaborative co-development arrangements that may include milestone payments, success fees, or equity structures. Sphaera works through an embedded-collaboration model tailored per project and partner, supplemented by strategic alliances such as the embedded collaboration with Aayam for access to global technologies. Customer acquisition is heavily event-driven, with active participation at BIO conventions (San Diego, Boston), Drug Discovery Chemistry, CPHI, Global Bio-India, and BioAsia. CEO Abhinav Dhandia leads global collaboration, business structuring, and commercialization, supported by an experienced leadership team with 80+ years of combined life sciences expertise. In June 2025, the company established Sphaera Biosciences Inc., a wholly owned US subsidiary, to expand direct access to the US biotech and pharmaceutical markets.

Name

Sphaera Pharma

Legal name

Sphaera Pharma Pvt Ltd

Website

https://sphaerapharma.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

101–250 employees

Short description

Sphaera Pharma is an India-headquartered preclinical drug discovery CRO founded in 2007, offering integrated medicinal chemistry, in-vitro pharmacology, and in-vivo pharmacology services to global pharmaceutical and biotech partners across oncology, metabolic, CNS, mitochondrial, and rare disease programs.

Ownership category

akta.pro rank

Product category

Preclinical Drug Discovery Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

DMPK / ADME & Bioanalysis (HLAGAFAC), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

Keywords

• Preclinical drug discovery
• Medicinal chemistry services
• In-vivo pharmacology
• Contract research organization
• Drug repurposing platform

Headquarters

HQ city

Haryana

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Integrated Drug Discovery Services: Fee-for-service preclinical R&D services including medicinal chemistry, in-vitro and in-vivo pharmacology provided to pharmaceutical and biotech partners. Revenue generated through project-based contracts with embedded collaboration models tailored for each project and partner.
2. Collaborative Drug Development: Strategic partnerships and co-development arrangements where Sphaera contributes scientific expertise and infrastructure to advance preclinical assets. May include milestone payments, success fees, or equity arrangements depending on the collaboration model.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Sphaera Pharma is an integrated drug discovery and development biotech that provides preclinical contract research services to pharmaceutical and biotech partners, spanning medicinal chemistry (NCE design, hit-to-lead, lead optimization, library design), in-vitro pharmacology (assay development, biomarker profiling, ADME) and in-vivo pharmacology (efficacy, safety and disease-specific models, rodent PK studies). The company also leverages proprietary platform technologies to accelerate, enable and repurpose drugs across oncology, metabolic disorders, CNS, mitochondrial dysfunction and rare genetic disorders.

Product overview

Sphaera Pharma is an integrated drug discovery and development biotech company that provides a comprehensive suite of services rather than a single software product. The company offers Chemistry Services (NCE design, synthesis, library design for heterocycles, steroids, PROTAC), In-Vitro Pharmacology Services (assay development, biomarker profiling, ADME studies), and In-Vivo Pharmacology Services (preclinical efficacy and safety models, pharmacokinetic studies). These services are supported by proprietary platform technologies enabling drug acceleration, enablement and repurposing across oncology, metabolic disorders, CNS, mitochondrial dysfunction and rare genetic disorders. The company operates through collaborative models with global partners including Aayam to access global technologies and capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Chemistry Services

Quantifiable outcome

• Multiple preclinical projects advanced into clinic for partners and patients
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• AayamcoreStrategic or Co-development Partner · 1 June 2025Sphaera has an embedded collaboration with Aayam, providing access to global technologies and capabilities across the drug discovery and development spectrum. This partnership enables Sphaera to leverage complementary resources and expand its service offerings to include global technology platforms.
• Sphaera Biosciences Inc., USAcoreOthers · 1 June 2025Wholly owned subsidiary of Sphaera Pharma Pvt Ltd established in June 2025. This US entity will focus on advancing novel drug discovery programs and harnessing the latest technologies to address critical unmet medical needs. The subsidiary synergizes Sphaera's Indian scientific operations with direct access to the dynamic US biotech and pharmaceutical markets.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Syngene International: India-based integrated CRO offering discovery, development, and manufacturing services across therapeutic areas. Directly comparable as a large-scale Indian preclinical CRO serving global pharma and biotech partners.
• Aragen Life Sciences (formerly GVK Biosciences): India-headquartered CRO providing integrated drug discovery and development services from medicinal chemistry through in-vivo pharmacology. Closely mirrors Sphaera's integrated preclinical platform model.
• Sai Life Sciences: India-based CRO offering drug discovery, development, and CDMO services. Directly comparable in offering integrated chemistry and biology services to global pharma partners.
• Anthem Biosciences: India-based integrated CRO providing drug discovery and development services including medicinal chemistry and in-vitro/in-vivo pharmacology. Comparable in scale and integrated service offering to Sphaera.
• Piramal Pharma Solutions: India-based CRO/CDMO with discovery, development, and manufacturing capabilities across multiple therapeutic areas. Comparable integrated preclinical-to-clinical services targeting global pharma.
• Jubilant Biosys: India-based integrated drug discovery CRO offering medicinal chemistry, in-vitro/in-vivo biology, and computational chemistry. Closely comparable in scale, geography, and integrated service model.

Broad incumbents

• Charles River Laboratories: Global preclinical CRO leader offering in-vivo pharmacology, safety assessment, and discovery services. Overlaps directly with Sphaera's in-vivo and safety capabilities but at much greater scale and geographic reach.
• WuXi AppTec: Global CRO/CDMO with extensive preclinical drug discovery and development capabilities. Competes for the same global pharma and biotech sponsors as Sphaera across chemistry and biology services.
• Eurofins Scientific: Global bioanalytical and preclinical testing services provider. Overlaps with Sphaera's bioanalytical, ADME, and biomarker capabilities as part of a much broader testing portfolio.

Regional players

• Suven Life Sciences: India-based drug discovery and development company with CNS-focused expertise. Comparable in geography and therapeutic area focus (notably CNS) but with more proprietary development orientation versus pure services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sphaera-pharma-pte-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sphaera Pharma